At the time of writing, Akebia Therapeutics Inc [AKBA] stock is trading at $2.05, up 6.22%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The AKBA shares have gain 12.64% over the last week, with a monthly amount glided 25.77%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on August 28, 2023, and kept the price target unchanged to $3.75. On May 31, 2023, upgrade upgraded it’s rating to Overweight and revised its price target to $4 on the stock. Piper Sandler downgraded its rating to a Neutral and decreased its price target to $2 on March 31, 2022. Needham downgraded its rating to a Hold. Mizuho downgraded its rating to Neutral for this stock on March 31, 2022, and downed its price target to $2. In a note dated March 31, 2022, H.C. Wainwright downgraded an Neutral rating on this stock and revised its target price from $10 to $2.
For the past year, the stock price of Akebia Therapeutics Inc fluctuated between $0.80 and $2.48. Currently, Wall Street analysts expect the stock to reach $6.5 within the next 12 months. Akebia Therapeutics Inc [NASDAQ: AKBA] shares were valued at $2.05 at the most recent close of the market. An investor can expect a potential return of 217.07% based on the average AKBA price forecast.
Analyzing the AKBA fundamentals
According to Akebia Therapeutics Inc [NASDAQ:AKBA], the company’s sales were 169.88M for trailing twelve months, which represents an -10.98% plunge. Gross Profit Margin for this corporation currently stands at 0.63% with Operating Profit Margin at -0.2%, Pretax Profit Margin comes in at -0.27%, and Net Profit Margin reading is -0.27%. To continue investigating profitability, this company’s Return on Assets is posted at -0.22, Equity is 1.3 and Total Capital is -0.25. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -0.76.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.9300 points at the first support level, and at 1.8200 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.1300, and for the 2nd resistance point, it is at 2.2200.
Ratios To Look Out For
It is important to note that Akebia Therapeutics Inc [NASDAQ:AKBA] has a current ratio of 1.52. As well, the Quick Ratio is 1.21, while the Cash Ratio is 0.52. Considering the valuation of this stock, the price to sales ratio is 2.63.
Transactions by insiders
Recent insider trading involved Hadas Nicole R., SVP, Chief Legal Officer, that happened on May 13 ’24 when 12016.0 shares were sold. SVP, Chief Operating Officer, Dahan Michel completed a deal on May 13 ’24 to sell 34840.0 shares. Meanwhile, SVP, Chief Operating Officer Dahan Michel sold 8661.0 shares on Feb 29 ’24.
